EpiCast Report: Multiple Sclerosis – Epidemiology Forecast to 2026

Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed by axon damage and paralysis. To forecast the diagnosed prevalent and diagnosed incident cases of MS in the 7MM, GlobalData epidemiologists selected nationally representative country-specific studies that used the McDonald criteria for the diagnosis of MS.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of MS in the 7MM will grow by an Annual Growth Rate (AGR) of 0.79% per year over the next 10 years, from 1,035,070 cases in 2016 to 1,116,491 cases in 2026. Of the 7MM, the US had the highest number of diagnosed prevalent cases with 421,329 cases in 2016, while Japan had the lowest number of diagnosed prevalent cases with 19,499 cases in 2016. In 2016, the US accounted for 40.71% of all the diagnosed prevalent cases of MS, while Japan accounted for only 1.88% of diagnosed prevalent cases of MS in the 7MM.

Scope

The Multiple sclerosis (MS) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends for MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of MS, segmented by sex and by age (for all ages) in these markets. The diagnosed prevalent cases are further segmented by types of MS (relapsing-remitting [RRMS], primary progressive [PPMS], and secondary progressive [SPMS]) in the 7MM.

The MS epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The MS EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global MS market.

Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MS therapeutics in each of the markets covered.

Understand magnitude of MS population by disease type.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Multiple Sclerosis Executive Summary

2.1 Related ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Multiple Sclerosis Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Diagnosed Prevalent Cases of MS

3.4.4 Diagnosed Prevalent Cases of MS by Types

3.4.5 Diagnosed Incident Cases of MS

3.5 Epidemiological Forecast for MS (2016–2026)

3.5.1 Diagnosed Prevalent Cases of MS

3.5.2 Age-Specific Diagnosed Prevalent Cases of MS

3.5.3 Sex-Specific Diagnosed Prevalent Cases of MS

3.5.4 Diagnosed Prevalent Cases of MS by Types

3.5.5 Diagnosed Incident Cases of MS

3.5.6 Age-Specific Diagnosed Incident Cases of MS

3.5.7 Sex-Specific Diagnosed Incident Cases of MS

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitation of Analysis

3.6.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

List of Tables

Table 1: Risk Factors and Comorbidities for MS

Table 2: 7MM, Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, Selected Years 2016–2026

Table ...

Table 1: Risk Factors and Comorbidities for MS

Table 2: 7MM, Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, Selected Years 2016–2026

Table 3: 7MM, Diagnosed Incident Cases of MS, Both Sexes, All Ages, Selected Years 2016–2026

List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, 2016 and 2026

Figure 2: 7MM, Diagnosed Incident Cases of MS, Both Sexes ...

Figure 1: 7MM, Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, 2016 and 2026

Figure 2: 7MM, Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016 and 2026

Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of MS (%), Both Sexes, All Ages, 2016

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of MS (Cases per 100,000 Population), Both Sexes, All Ages, 2016

Figure 5: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of MS

Figure 6: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of MS

Figure 7: 7MM, Sources Used and Not Used for the Diagnosed Prevalent Cases of MS by Types

Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, 2016

Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, 2016

Figure 10: 7MM, Diagnosed Prevalent Cases of MS by Types, Both Sexes, All Ages, 2016

Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016

Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports